TFM
MCRB icon

TFC Financial Management’s Seres Therapeutics MCRB Stock Holding History

TFC Financial Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$701 – 1040
2025
Q1 		$701 Hold
50
– – ﹤0.01% 598
2024
Q4 		$831 Hold
50
– – ﹤0.01% 591
2024
Q3 		$947 Hold
50
– – ﹤0.01% 593
2024
Q2 		$724 Hold
50
– – ﹤0.01% 594
2024
Q1 		$775 Buy
+50
New +$1.08K ﹤0.01% 581

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

TFC Financial Management's MCRB Position: Q2 2025 in Review

TFC Financial Management sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 50 shares — an estimated $701 sold.

TFC Financial Management first reported a position in MCRB in Q1 2024 and held it in 5 quarters. The position peaked at $947 in Q3 2024. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • TFC Financial Management reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • TFC Financial Management sold 50 Seres Therapeutics shares in Q2 2025, an estimated $701.
  • TFC Financial Management first reported a position in Seres Therapeutics in Q1 2024 and held it in 5 quarters.
  • TFC Financial Management's Seres Therapeutics position peaked at $947 in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on TFC Financial Management's 13F filing for Q2 2025, filed 29 Jul 2025.